Name: CW-3308
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Appearance

White to off-white solid

Storage

Store at -20 °C

IUPACName

2-(2,6-dioxopiperidin-3-yl)-6-[[3-[4-(2-ethyl-1-oxo-2,7-naphthyridin-4-yl)-2,6-dimethoxybenzoyl]-3-azaspiro[5.5]undecan-9-yl]methyl]-5,7-dihydropyrrolo[3,4-f]isoindole-1,3-dione

Synonyms

CW 3308; CW3308

InChI Key

ZXEZSPAYGZVVCZ-UHFFFAOYSA-N

InChI

InChI=1S/C45H48N6O8/c1-4-49-25-34(30-9-14-46-21-33(30)41(49)54)27-19-36(58-2)39(37(20-27)59-3)44(57)50-15-12-45(13-16-50)10-7-26(8-11-45)22-48-23-28-17-31-32(18-29(28)24-48)43(56)51(42(31)55)35-5-6-38(52)47-40(35)53/h9,14,17-21,25-26,35H,4-8,10-13,15-16,22-24H2,1-3H3,(H,47,52,53)

SMILES

CCN1C=C(C2=C(C1=O)C=NC=C2)C3=CC(=C(C(=C3)OC)C(=O)N4CCC5(CCC(CC5)CN6CC7=CC8=C(C=C7C6)C(=O)N(C8=O)C9CCC(=O)NC9=O)CC4)OC

Mechanism

Target: CW-3308 selectively targets BRD9, a SWI/SNF-associated bromodomain protein.

Binding site: Its BRD9 ligand binds the bromodomain acetyl-lysine recognition pocket.

Mechanism of action: CW-3308 is a cereblon-recruiting BRD9 PROTAC optimized for potent and selective BRD9 degradation. It contains a BRD9 bromodomain ligand, a linker, and a thalidomide-derived CRBN ligand, allowing BRD9 recruitment to CRL4CRBN ubiquitin ligase machinery. Productive ternary-complex formation drives BRD9 ubiquitination and proteasome-dependent depletion while maintaining selectivity over related bromodomain proteins such as BRD7 and BRD4 in reported studies. CW-3308 is useful for studying BRD9-dependent chromatin regulation, SWI/SNF-associated transcriptional programs, degradation selectivity, and cellular responses in BRD9-dependent tumor models.

Applications

• PROTAC-Mediated Kinase Degradation: CW-3308 is designed for the targeted degradation of specific kinases, allowing researchers to dissect kinase signaling pathways and their roles in cellular processes. This application aids in elucidating the mechanisms of kinase-related diseases and developing novel therapeutic strategies.

• Targeted Degradation in Cancer Research: By employing CW-3308, researchers can selectively degrade oncogenic proteins, providing insights into cancer cell biology and potential vulnerabilities. This approach facilitates the identification of new drug targets and the development of innovative cancer treatments.

• Studying Protein-Protein Interactions: CW-3308 enables the targeted degradation of proteins involved in critical protein-protein interactions. This application helps uncover the functional relevance of these interactions in various biological contexts, advancing our understanding of cellular dynamics and disease mechanisms.

• Investigating Protein Stability: Utilizing CW-3308 allows scientists to explore the stability and turnover of target proteins. This application is essential for studying protein homeostasis and its impact on cellular function, offering valuable information for drug discovery and development.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂